Meghara Walsh

发表

Neoadjuvant dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin with pegfilgrastim support in muscle-invasive urothelial cancer: pathologic, radiologic, and biomarker correlates.

P. Kantoff, A. Kibel, S. Signoretti, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase Ib dose-escalation study of TRC105 (anti-endoglin antibody) in combination with axitinib in patients with metastatic renal cell carcinoma.

T. Choueiri, M. Michaelson, G. Sonpavde, 2014 .

Clinical Results and Biomarker Analyses of Axitinib and TRC105 versus Axitinib Alone in Patients with Advanced or Metastatic Renal Cell Carcinoma (TRAXAR).

K. Owzar, T. Ho, T. Choueiri, 2021, The oncologist.

CABOzantinib versus SUNitinib (CABOSUN) as initial targeted therapy for patients with metastatic renal cell carcinoma (mRCC) of poor and intermediate risk groups: Results from ALLIANCE A031203 trial

T. Choueiri, T. Olencki, M. Morris, 2016 .

Cabozantinib Versus Sunitinib As Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma of Poor or Intermediate Risk: The Alliance A031203 CABOSUN Trial.

T. Choueiri, M. Michaelson, T. Olencki, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase 1 study of buparlisib and bevacizumab in patients with metastatic renal cell carcinoma progressing on vascular endothelial growth factor‐targeted therapies

E. V. Van Allen, S. Signoretti, T. Choueiri, 2016, Cancer.

Cabozantinib versus sunitinib as initial therapy for metastatic renal cell carcinoma of intermediate or poor risk (Alliance A031203 CABOSUN randomised trial): Progression-free survival by independent review and overall survival update

T. Choueiri, M. Michaelson, T. Olencki, 2018, European journal of cancer.

Radium-223 Dichloride in Combination with Vascular Endothelial Growth Factor–Targeting Therapy in Advanced Renal Cell Carcinoma with Bone Metastases

T. Choueiri, M. Michaelson, J. Bellmunt, 2018, Clinical Cancer Research.

Cabozantinib Versus Sunitinib for Untreated Patients with Advanced Renal Cell Carcinoma of Intermediate or Poor Risk: Subgroup Analysis of the Alliance A031203 CABOSUN trial

T. Choueiri, M. Michaelson, M. Morris, 2019, The oncologist.

An Open Label Phase Ib Dose Escalation Study of TRC105 (Anti-Endoglin Antibody) with Axitinib in Patients with Metastatic Renal Cell Carcinoma.

T. Choueiri, M. Michaelson, G. Sonpavde, 2018, The oncologist.

An Open Label Phase Ib Dose Escalation Study of TRC 105 ( Anti-Endoglin Antibody ) with Axitinib in Patients with Metastatic Renal Cell Carcinoma

Posadas, Andrew, Nixon, 2018 .

A phase II multicenter study of neoadjuvant dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin (ddMVAC) chemotherapy with pegfilgrastim support in patients (pts) muscle-invasive urothelial cancer (MIUC): Safety, pathologic, radiologic, and molecular correlates.

S. Signoretti, G. Bubley, G. Steele, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Corrigendum to ‘Cabozantinib versus sunitinib as initial therapy for metastatic renal cell carcinoma of intermediate or poor risk (Alliance A031203 CABOSUN randomised trial): Progression-free survival by independent review and overall survival update’ [Eur J Cancer 94 (May 2018) 115–125]

T. Choueiri, M. Michaelson, T. Olencki, 2018, European journal of cancer.

LBA38Progression-free survival (PFS) by independent review and updated overall survival (OS) results from Alliance A031203 trial (CABOSUN): Cabozantinib versus sunitinib as initial targeted therapy for patients (pts) with metastatic renal cell carcinoma (mRCC)

T. Choueiri, T. Olencki, M. Morris, 2017 .

854PDPazopanib (p) or sorafenib (s) + radium-223 (rad) in metastatic renal cell carcinoma (mrcc) with bone metastases (bm)

T. Choueiri, M. Michaelson, J. Bellmunt, 2017 .

Results of a phase II study of atezolizumab and bevacizumab in non-clear cell renal cell carcinoma (nccRCC) and clear cell renal cell carcinoma with sarcomatoid differentiation (sccRCC).

S. Signoretti, T. Choueiri, B. McGregor, 2019, Journal of Clinical Oncology.

Evaluating a Video-Based, Personalized Webpage in Genitourinary Oncology Clinical Trials: A Phase 2 Randomized Trial

T. Choueiri, L. Polacek, L. Werner, 2018, Journal of medical Internet research.

Atezolizumab plus bevacizumab in non-clear cell renal cell carcinoma (NccRCC) and clear cell renal cell carcinoma with sarcomatoid differentiation (ccRCCsd): Updated results of activity and predictive biomarkers from a phase II study.

S. Signoretti, T. Choueiri, B. McGregor, 2019, Journal of Clinical Oncology.